Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427090 | 1.00 | KDM1A (0.44) | KDM1AMAOAMAOBMPOCCR1 | |
| Formic Acid Methyl Ester SCHEMBL31051630 | 0.89 | KDM1A (0.39) | KDM1AMAOAMAOBMPOCCR1 | |
| SCHEMBL217520 | 0.81 | KDM1A (0.45) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL29525054 | 0.79 | KDM1A (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL10568321 | 0.79 | MPO (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL29907787 | 0.79 | MPO (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL9991287 | 0.79 | KDM1A (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL128108 | 0.79 | KDM1A (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL509881 | 0.79 | KDM1A (0.44) | KDM1AMAOAMAOBMPOBTK | |
| SCHEMBL8477471 | 0.79 | KDM1A (0.44) | KDM1AMAOAMAOBMPOBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271239-B | Synthesis method of 3- (6-methoxy-2-pyridine) -propionic acid | 聊城大学 | 2025-02-11 | — | — | CN | claimed |
| CN-118271239-A | Synthesis method of 3- (6-methoxy-2-pyridine) -propionic acid | 聊城大学 | 2024-07-02 | — | — | CN | claimed |
| CN-111825619-A | Benzimidazole derivative and application thereof | 济南大学 | 2020-10-27 | — | — | CN | claimed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4587443-A1 | MACROCYCLIC CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| CN-118271239-A | Synthesis method of 3- (6-methoxy-2-pyridine) -propionic acid | 聊城大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271239-A | Synthesis method of 3- (6-methoxy-2-pyridine) -propionic acid | 聊城大学 | 2024-07-02 | — | — | CN | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1158610-A | Quinoxaline derivatives useful in therapy | PFIZER LTD (IE) | 1997-09-03 | — | — | CN | disclosed |
| EP-0783495-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | Pfizer Limited (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-4426526-A | HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY, ANTISECRETORY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-01-17 | — | — | US | disclosed |
| US-4264608-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-04-28 | — | — | US | disclosed |
| US-4215126-A | HISTAMINE H2 BLOCKING | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-29 | — | — | US | disclosed |
| US-4156727-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-29 | — | — | US | disclosed |
| US-4154838-A | ANTIHISTAMINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | KDM1A 4207/4885MAOA 2403/4885MAOB 3350/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | KDM1A 2826/4885MAOA 1873/4885MAOB 1233/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KDM1A 2647/4885MAOA 118/4885MAOB 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.